JCR Pharmaceuticals Co.,Ltd. (4552.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	38.5B	40.3B	33.1B	42.9B	34.3B
Cost of Revenue	2.4B	10.1B	11.3B	11.6B	8.9B
Gross Profit	6.2B	30.2B	21.7B	31.3B	25.5B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	6.8B	29.6B	28.4B	23.7B	20.5B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	6.8B	29.6B	28.4B	23.7B	20.5B
Cost and Expenses	42.0B	39.8B	39.7B	35.3B	29.4B
Operating Income (EBIT)	(3.4B)	555.0M	(6.7B)	7.5B	5.0B
Non-Operating
Interest Income	9.0M	81.0M	113.0M	111.0M	33.0M
Interest Expense	79.0M	398.0M	155.0M	86.0M	44.0M
Net Interest Income	(70.0M)	(317.0M)	(42.0M)	25.0M	(11.0M)
Other Non-Op Income/Expense	(144.0M)	610.0M	(828.0M)	(268.0M)	442.0M
Non-Operating Income (excl Interest)	65.0M	1.4B	147.0M	945.0M	508.0M
EBT (Pre-Tax Income)	(751.0M)	3.2B	(6.4B)	7.2B	5.4B
Income Tax Expense	(180.0M)	1.0B	(1.7B)	1.7B	1.6B
Bottom Line
Net Income	(2.1B)	2.2B	(4.8B)	5.5B	3.8B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(2.1B)	2.2B	(4.8B)	5.5B	3.8B
Per Share
Basic EPS	(¥16)	¥18	(¥38)	¥44	¥30
Diluted EPS	(¥16)	¥18	—	¥44	¥30
Revenue Per Share	¥316	¥331	¥267	¥344	¥276
Shares
Basic Shares Outstanding	121.9M	121.9M	123.8M	124.8M	124.3M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	3.1B	(3.3B)	10.7B	7.0B
D&A	—	2.6B	3.4B	3.2B	2.0B
EBIT	(3.4B)	555.0M	(6.7B)	7.5B	5.0B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026